Ex-US FDA official Li Zili to head Hong Kong medical products regulator

Hong Kong appoints Li Zili, a Beijing-educated former US FDA official, as controller for medical products regulation, effective October 20, to accelerate clinical adoption of medicines and devices. The move signals a regulatory overhaul aimed at streamlining approvals, though its impact on drug access timelines remains uncertain. This is a notable personnel decision in Hong Kong's health governance, potentially aligning local standards more closely with international practices.